The aquired immune deficiency syndrome pandemic has altered transfusion practices. Indications for red blood cells and other components have changed; red cell substitutes are being actively pursued and substances that stimulate production of formed elements have been introduced into clinical practice. Pharmacologic agents designed to decrease surgical blood loss are being used in a variety of procedures. The effect of allogeneic blood on the immune system is a matter of significant concern. Although a zero-risk blood supply is probably not achievable, it is essential that patients are not denied life-saving therapy because of unrealistic fears about complications of transfusion.
展开▼
